Who owns AVANIR Pharmaceuticals?

Key details on AVANIR Pharmaceuticals (Ticker: AVNR)

Who owns AVANIR Pharmaceuticals?

Is AVNR a good stock to own? Find out who bought AVANIR Pharmaceuticals, who sold AVANIR Pharmaceuticals (AVNR) stock, and who holds a large position in AVANIR Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
T. Rowe Price Associates 25.65M $94.15M March 31, 2014
FMR 12.20M $44.89M March 31, 2014
BlackRock Fund Advisors 7.56M $27.75M March 31, 2014
STATE STREET CORPORATION 6.87M $25.21M March 31, 2014
Baker Bros. Advisors 5.79M $21.25M March 31, 2014
Millennium Management 5.18M $19.01M March 31, 2014
Invus Public Equities Advisors 5.15M $17.30M June 30, 2011
BlackRock Institutional Trust Company, N.A. 4.76M $17.48M March 31, 2014
Vanguard 4.67M $17.13M March 31, 2014
TimesSquare Capital Management 4.20M $15.40M March 31, 2014
Ulys 3.65M $12.48M March 31, 2012
Artal Group S.A. 3.40M $14.38M Sept. 30, 2013
GOLDMAN SACHS 3.04M $11.16M March 31, 2014
Wellington Management Company 2.60M $9.53M March 31, 2014
SUSQUEHANNA INTERNATIONAL 2.44M $8.96M March 31, 2014
BVF 2.44M $10.33M Sept. 30, 2013
Adage Capital Partners GP 2.30M $10.58M June 30, 2013
NORTHERN TRUST 1.93M $7.09M March 31, 2014
Credit Suisse AG 1.89M $6.92M March 31, 2014
OrbiMed Advisors 1.86M $7.88M Sept. 30, 2013
Tang Capital Management 1.56M $3.20M Dec. 31, 2011
Barclays 1.46M $4.37M March 31, 2014
CalPERS 1.38M $2.83M Dec. 31, 2011
Deerfield Management Company 1.28M $4.39M March 31, 2012
Allianz Asset Management AG 1.22M $5.17M Sept. 30, 2013
Driehaus Capital Management 1.10M $3.68M Dec. 31, 2013
Thomas Weisel Asset Management 1.08M $2.21M Dec. 31, 2011
Ascend Capital 979370 $4.14M Sept. 30, 2013
Hambrecht & Quist Capital Management 960000 $4.07M Sept. 30, 2013
CR Intrinsic Investors 898538 $4.13M June 30, 2013
J. Goldman & Co 837500 $3.07M March 31, 2014
S.A.C. Capital Advisors 827300 $2.18M Dec. 31, 2012

Who sold AVANIR Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
QVT Financial Sept. 30, 2011 1.06M $3.01M